Purpose Bone pain is a common side effect of pegfilgrastim and can interfere with quality of life and treatment adherence. This study investigated the impact of antihistamine prophylaxis on pegfilgrastim-induced bone pain. Methods This is a two-stage enrichment trial design. Patients receiving an initial dose of pegfilgrastim after chemotherapy were enrolled into the observation (OBS) stage. Those who developed significant back or leg bone pain (SP) were enrolled into the treatment (TRT) stage and randomized to daily loratadine 10 mg or placebo for 7 days. SP was defined by Brief Pain Inventory as back or leg pain score ≥5 and a 2-point increase after pegfilgrastim. The primary end point of TRT was reduction of worst back or leg bone pain with loratadine, defined as a 2-point decrease after treatment compared to OBS. Results Two hundred thirteen patients were included in the final analysis. Incidence of SP was 30.5 %. The SP subset had a worse overall Functional Assessment of Cancer Therapy-Bone Pain score (33.9 vs. 51.7, p < 0.001) and a higher mean white blood cell count (15.4 vs. 8.4 K/cm 3 , p = 0.013) following pegfilgrastim than those without SP. Forty-six patients were randomized in the TRT. Benefit was 77.3 % with loratadine and 62.5 % with placebo (p = 0.35). Baseline NSAID use was documented in four patients (18.2 %) in loratadine arm and two patients (8.3 %) in placebo arm, with baseline non-NSAID use documented in five (22.7 %) and six (25 %) patients, respectively. Eight additional patients used NSAIDS by day 8 compared to day 1 (six in the loratadine and two in the placebo arm). A total of six additional patients used non-NSAIDS by day 8 compared to day 1 (four in the loratadine and two in the placebo arm). Conclusions Administration of prophylactic loratadine does not decrease the incidence of severe bone pain or improve quality of life in a high-risk patient population.
Introduction
Filgrastim (G-CSF) is a recombinant hematopoietic myeloid growth factor that selectively stimulates the proliferation and differentiation of neutrophil precursors. Pegfilgrastim is a 20-kDa polyethylene glycol carrier of filgrastim that is covalently bound at the N-terminal residue. Randomized trials have demonstrated that a single dose of pegfilgrastim offers neutrophil support comparable to multiple once-daily doses of filgrastim [1, 2] . G-CSF and pegfilgrastim are used to reduce infection risk associated with neutropenia and febrile neutropenia in patients receiving myelosuppressive chemotherapy [3] . They can also be administered prophylactically to maintain chemotherapy intensity or dose density. The most common adverse event of G-CSF and pegfilgrastim is bone pain with an overall incidence of 36 to 70 % in cancer patients [4] [5] [6] . The pain, which is primarily located in the back and legs, generally appears within 2 days of pegfilgrastim administration and lasts for 2-4 days [7] . This pain can be controlled with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, and opioids. Only naproxen has been studied in a randomized trial. Prevention with this agent reduces incidence and severity of pegfilgrastim-induced bone pain, but over 60 % of patients still experienced some pain [4] .
No patient risk factors have been identified that are predictive for pegfilgrastim-induced pain [4, 8] , and the exact mechanisms of G-CSF-induced pain have yet to be elucidated. Possible pathways include bone marrow expansion, peripheral nociceptor sensitization, immune function modulation, and direct effect on bone metabolism [6, 9] . G-CSF modulates local and systemic inflammatory responses through histamine, which acts as a chemical mediator of inflammation and local edema [10] [11] [12] , causing both nociceptive c-fiber-mediated and neuropathic pain [13] . Antihistamines have a direct adjuvant analgesic activity [14] . Several case reports [15, 16] and a small pilot study [17] have suggested antihistamine efficacy in the prevention of pegfilgrastim-induced pain. To determine the merits of this strategy, we hypothesized that loratadine, a second-generation type 1 antihistamine [18] , would decrease the incidence of pegfilgrastim-induced significant back or leg bone pain (SP), and performed a randomized trial in a highrisk population.
Patients and methods

Study design
This is a randomized multicenter phase II enrichment design study of loratadine versus placebo for pegfilgrastim-induced bone pain. The study included an observation (OBS) stage followed by a treatment (TRT) stage (Fig. 1 ). Subjects were consented if they were to receive pegfilgrastim, 6 mg subcutaneously, for the first time with chemotherapy. Each participant signed an IRB-approved, protocol-specific informed consent in accordance with federal and institutional guidelines. All procedures were in accordance with the ethical standards of the local institutional review board and with the 1964 Helsinki declaration and its later amendments.
All consented patients completed screening surveys to determine incidence of pegfilgrastim-induced pain during OBS. Subjects who developed significant pain (SP) were eligible to enter TRT and were randomized to loratadine 10 mg or a matched placebo daily for 7 days starting on the day of pegfilgrastim administration. Loratadine treatment benefit and the incidence of worst back and leg pain were compared between study arms in TRT patients.
Patient eligibility
Patients 18 years of age or older with an ECOG performance status of 0 to 3, with adequate renal function (estimated CrCl >30 ml/min) and hepatic function (AST ≤2.5 × ULN, ALT ≤2.5 × ULN, total bilirubin ≤2.5 × ULN) were eligible for the trial if they had histologically or cytologically documented malignancy and were scheduled to receive pegfilgrastim with two consecutive cycles of the same chemotherapy with at least a 14-day interval between cycles. Patients were excluded if there was a history of hypersensitivity or intolerance to antihistamines or concurrent use of antihistamines during or for 2 days prior to the study period except for a single dose of antihistamine as required for the administration of chemotherapy or blood transfusion. Other exclusion criteria were concomitant use of amiodarone or history of prior use of pegfilgrastim or G-CSF.
Analgesic use at baseline was permitted. Rescue use of analgesics during OBS and TRT was recorded and categorized as NSAID vs. non-NSAID (acetaminophen and opioid analgesics). Patients were instructed not to use analgesics prophylactically in the absence of pain or for other indication. CBC results were recorded on day 1 and day 8 of both OBS and TRT.
Randomization
Subjects who developed SP during the OBS were randomized 1:1 to loratadine or placebo, stratified on taxane use. At the time of study initiation, each of seven participating sites designated a pharmacist who would remain unblinded for the duration of the study to assign new subjects consecutively according to a list of arm assignments that had been randomly ordered based on a block design. All patients, treatment team, and research staff were blinded to treatment status.
Assessments
During both OBS and TRT, bone pain was assessed by standardized questionnaires on day 1 before treatment and on day 8 after the administration of pegfilgrastim, assessing pain experienced during the previous 7 days. Questionnaires during both OBS and TRT were self-administered with a research staff available for assistance or clarification if necessary. The Worst Pain (WPS) and Average Pain Scales (APS) of the Brief Pain Inventory and the Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP) for functional effects of pain were used in this study [19, 20] . WPS and APS of the Brief Pain Inventory are questionnaires assessing the rate of worst or average back and leg pain, respectively. A higher score reflects higher pain severity (0-10). The questionnaire also contains the front and back diagrams of the entire body, asking the patient to shade the areas of pain. FACT-BP is a 15-item questionnaire, assessing cancer-related bone pain and its effect on quality of life. Each question is answered on a graduated scale (0-4). A lower aggregate score reflects higher bone pain and/or worse quality of life [19] .
To be enrolled in TRT, patients had to have back and leg SP based on WPS, defined as a score ≥5 on day 8 and a 2-point increase during the 7 days of OBS after pegfilgrastim use. This definition of SP aims to incorporate both severity and change in pain in response to pegfilgrastim. Although not validated in this setting, there is evidence in support of a score of ≥l as corresponding to moderate pain at minimum and an absolute change of 2 as meaningful [21, 22] . The primary end point was benefit from loratadine prophylaxis, defined as a reported decrease in WPS difference from days 1 to 8 of at least 2 points between OBS and TRT. All sites of bony pain were recorded in the questionnaires in addition to the back and legs. Compliance was assessed via day 8 pill counts during TRT.
Statistical analysis
Descriptive statistics were obtained for all measures. Ordinal and quantitative measures were summarized with means, standard deviations, and ranges supplemented with 95 % confidence intervals. Binary data percentages were supplemented
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The primary outcome comparison between the two randomized treatment arms used an intent-to-treat approach and was made using the Fisher's exact test and a 5 % type I error level. A target sample size of 55 patients for the TRT of the trial was based on the following assumptions: a 30 % incidence of SP during the OBS, a 10 % benefit with placebo compared to a 50 % benefit with loratadine for the randomized TRT, and a 89 % power using a nondirectional chi-square test with a 5 % type I error level. Statistical calculations and data management were conducted using SYSTAT (ver. 11) and StatXact (ver. 4.0).
Results
The study was conducted at seven sites in VT, NY, and ME. Between February of 2011 and December of 2013, 227 patients were enrolled in the OBS, 213 of whom were included in the final analysis. Fourteen patients provided incomplete responses to pain questionnaires. The CONSORT flow diagram is shown in Fig. 1 , and baseline demographic and clinical variables are provided in Table 1 .
Observation stage
Impact of pegfilgrastim on bone pain incidence SP occurred in 30.5 % (65/213, CI 24.4-37.2 %). In the entire cohort, the average WPS scores increased from 1.6 (CI 1.4-2.1) at baseline to 3.6 (CI 3.1-4.0) during the 8 days following the administration of the pegfilgrastim (p < 0.001). In particular, there were 111 cases where WPS scores were greater at follow-up on day 8 compared to their day 1 baseline, in contrast to only 27 cases with the opposite trend. Figure 2 depicts the distribution of the severity of bone pain before and after pegfilgrastim administration and shows a shift to higher pain intensity after treatment.
Compared to the subset without SP at day 8, those with SP had a worse overall score on the FACT-BP questionnaire reflecting the increase in bone pain and its effect on quality of life. At day 8 of OBS, the subset with SP also had a higher number of painful sites and higher intensity of both WPS and APS (Table 2 ). Patients with SP had a significantly higher prevalence of pain at day 8 at several sites including the shoulders, back, hips and legs compared those without SP at day 8 (Fig. 3) . Exploratory factor analysis indicated that patients in the SP group were more likely to experience pain at day 8 in , with a corresponding ANC of 4.6 (CI 4.1-5.1) to 6.9 (CI 4.9-8.8), respectively. The counts at day 8 were significantly greater in the SP compared to the non-SP subsets for both WBC (p = 0.013) and ANC (p = 0.039). These results were confirmed by within-subject comparisons between day 1 and day 8 (data not shown).
Treatment stage: efficacy of loratadine
Of the 65 (30.5 %) of patients who developed SP, 46 were randomized in TRT (22 in loratadine arm, 24 placebo arm) with one patient not receiving the allocated treatment and one lost to follow-up (Fig. 1) . Compliance with prophylaxis was excellent. Demographic and clinical characteristics of these patients are shown in Table 3 . Gender, age, malignancy type, and taxane use were all similarly distributed in loratadine vs. placebo groups, with the exception of proportion of males which is higher in the loratadine arm (36.4 vs 12.5 %). As observed in OBS, taxane therapy caused more frequent SP compared to non-taxane treatment (71.4 vs. 30.4 %, p = 0.015) in TRT. A total of eight additional patients used NSAIDS by day 8 compared to day 1 (six in the loratadine group and two in the placebo group). A total of six additional patients used non-NSAIDS by day 8 compared to day 1 (four in the loratadine group and two in the placebo group) ( Table  3) .
The primary end point of the randomized TRT was analgesic benefit from loratadine prophylaxis. In the intent-to-treat population, the rate of benefit was 17/22 (77.3 %, CI 54.6-92.2 %) in the loratadine arm and 15/24 (62.5 %, CI 40.6-81.2 %) in the placebo arm (p = 0.35). In the loratadine arm, WPS scores climbed from 1.9 (CI 0.8-3.1) to 4.7 (CI 3.46-6.1) with pegfilgrastim therapy. Corresponding WPS levels in the placebo arm were 2.5 (CI 1.1-3.9) and 4.6 (CI 3.1-6.0), respectively. Eleven patients in each arm developed SP.
An exploratory subset analysis of the primary outcome in the subset receiving taxane-containing chemotherapy revealed that 10/11 (90.9 %) met the primary end point from loratadine prophylaxis compared to only 3/11 (27. arm (p = 0.008). However, taxane therapy was associated with an increase in WPS scores after pegfilgrastim regardless of whether a patient received loratadine (1.73 increased to 5.00, p < 0.001) or placebo (1.70 increased to 6.00, p = 0.007).
Treatment stage: quality of life
For patients in TRT, analysis of the data showed no significant difference between day 1 FACT-BP scores between study arms (p = 0.330), or change in mean FACT-BP scores between the time before and after pegfilgrastim use within each arm. In the loratadine group, mean FACT-BP score was 50.7 (CI 44.5-55.9) at baseline and 48.1 (CI 43.7-52.5) at day 8 (p = 0.416). Corresponding scores in the placebo group were 46.8 (CI 40.6-53.1) and 47.9 (CI 44.0-51.7) (p = 0.677).
Discussion
Pegfilgrastim-induced bone pain is common and can interfere with a patient's quality of life and treatment adherence. This study was designed as a randomized phase II trial to (i) characterize the nature and extent of bony pain associated with pegfilgrastim therapy and (ii) investigate the impact of antihistamine prophylaxis on SP. The two-stage enrichment design allowed the selection of patients with severe pain while excluding the patients with mild to moderate pain. There are many definitions of severe bone pain in the literature. Reports have used CTCAE grading, classification into mild/moderate/ severe categories, or use of the WPS of the Brief Pain Inventory, leading to differences in the reported incidence of pain [4, 5, 23] . In this study, we defined severe pain as a WPS score of ≥5 to capture a population with moderate to severe pain and we controlled for baseline pain.
Analysis of the OBS data answered several important questions, including the observation of a 30.5 % incidence of pegfilgrastim-induced SP and positive correlation between the pain severity and the use of taxanes. The most common sites of pegfilgrastim-induced pain were the back, legs, and hips. Participants with severe bone pain had an inferior quality of life per FACT-BP aggregate score. The incidence of SP in our study is consistent with a 27.0 % incidence in the placebo group of a randomized study of naproxen vs. placebo [4] using a similar definition of severe pain as a score of 5 on the WPS but without adjustment for baseline pain. In contrast, a recent study of 2408 first-time stem cell donors receiving high-dose G-CSF revealed that over 80 % of donors experienced bone pain by day 4 of therapy, but only 9 % characterized their bone a NSAID and non-NSAID use unknown at day 1 in one (4.5 %) and three (12.5 %) of participants in the loratadine and placebo arms, respectively b NSAID and non-NSAID use unknown at day 8 in two (9.1 %) and three (12.5 %) of participants in the loratadine and placebo arms, respectively c Treatment stage d On day 1, 0 and 1 patient used both NSAID and Non-NSAID in the loratadine and placebo arms, respectively e On day 8, 3 and 1 patients used both NSAID and non-NSAID in the loratadine and placebo arms, respectively pain as severe [24] . Similar to our own results, the stem cell donor cohort reported bone pain most often in the axial skeleton, especially the back, hips, and pelvis [24] . There was a positive correlation between pain severity and the elevation of WBC and ANC counts. These laboratory marker variations may be related to the pathophysiology of pegfilgrastim-induced pain, which includes bone marrow expansion [6] . To our knowledge, there are no previous reports regarding the correlation between the severity of pegfilgrastim-induced bone pain and ANC and WBC counts. If validated, these may serve as biomarkers for the development of pegfilgrastim-induced SP.
Loratadine prophylaxis in TRT did not significantly reduce SP compared to placebo in a high-risk population. Our results differ from a pilot study demonstrating lower pegfilgrastiminduced pain severity measured as AUC for pain over a 5-day period [17] . A randomized phase 2 study comparing prophylactic naproxen and loratadine in breast cancer subjects is closed to accrual but not reported [25] . Reasons for differing results can be found in inherent limitations in our trial. One limitation of this study design was that participants were permitted to use analgesics for bone or other pain. Use of these agents was captured on the questionnaires, and there were differences between arms in the use of both NSAID and non-NSAID analgesia, although numbers are too small for adjustment. A second potential limitation is the reliance upon a questionnaire (FACT-BP) that is validated for use in chronic rather than transient bone pain. It was also administered only at two time points during 2 cycles of chemotherapy, relying on patient recall of their pain experience. We also used a definition of SP with a lower pain threshold of 5/10, which may have included patients with less than severe pain. Another limitation is the small sample size for OBS. Lastly, there is evidence in the literature that G-CSF-induced bone pain improves with subsequent cycles [5, 26] , which may dilute a potential benefit with prophylaxis. In our study, only 11 patients in the placebo arm (47.8 %) developed SP in TRT, confirming this observation.
Randomization was stratified by the use of taxane-based chemotherapy given the expected association between the use of this class of agents and both arthralgias and myalgias [27] . Antihistamines are reported to relieve taxane-induced arthralgias and myalgias [27, 28] . Pegfilgrastim use is also associated with joint and muscle pain along with classic bone pain [23] . Although the questionnaire focused on global bone pain independently of cause, taxane therapy was associated with more frequent pegfilgrastim-induced SP compared to nontaxane treatments in both stages of this trial. An exploratory analysis demonstrating that 90.9 % of patients receiving taxane-containing chemotherapy benefited from loratadine prophylaxis compared to only 27.3 % in the placebo arm (p = 0.008) may in part reflect effective loratadine prophylaxis of taxane-induced pain.
This study demonstrated that prophylactic administration of the antihistamine loratadine at standard dose does not decrease the incidence of significant pegfilgrastim-induced bone pain or improve quality of life in patients at higher risk of developing pain, but subsequent elevation of the neutrophil count following pegfilgrastim is correlated with a higher incidence of severe bone pain. While current evidence does not support the use of loratadine for bone pain, future clinical trials with a larger population receiving taxanes should address the possibility of efficacy in this particular group.
